LLLeonardo Lucantoni

Leonardo Lucantoni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leonardo Lucantoni has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Vicky M. Avery

    Discovery Biology, Griffith University, Brisbane Innovation Park, Don Young Road, Nathan 4111, Queensland, Australia

    4 shared publications
  • Sandra Duffy

    Discovery Biology, Griffith University, Brisbane Innovation Park, Don Young Road, Nathan 4111, Queensland, Australia

    3 shared publications
  • Vicky Marie Avery

    Discovery Biology, Centre for Cellular Phenomics, Griffith University, Nathan, Queensland, 4111, Australia; School of Environment and Science, Griffith University, Nathan, Queensland, 4111, Australia

    3 shared publications
  • Angelika Sturm

    TropIQ Health Sciences, Transistorweg 5-C02, 6534 AT Nijmegen, The Netherlands

    2 shared publications
  • Anthony C. Willis

    School of Chemistry , The Australian National University , Canberra , Australian Capital Territory 2601 , Australia

    2 shared publications
  • Anthony Richard Carroll

    Griffith University

    2 shared publications

Latest Publications

  • Open Access

    Discovery and Structure–Activity Relationships of Quinazolinone-2-carboxamide Derivatives as Novel Orally Efficacious Antimalarials

    by Benoît Laleu, Yuichiro Akao, Atsuko Ochida, Sandra Duffy, Leonardo Lucantoni, David M. Shackleford, Gong Chen, Kasiram Katneni, Francis C. K. Chiu, Karen L. White, et al.

    A phenotypic high-throughput screen allowed discovery of quinazolinone-2-carboxamide derivatives as a novel antimalarial scaffold. Structure–activity relationship studies led to identification of a potent inhibitor 19f, 95-fold more potent than the original hit compound, active against laboratory-resistant strains of malaria. Profiling of 19f suggested a fast in vitro killing profile. In vivo activity in a murine model of human malaria in a dose-dependent manner constitutes a concomitant benefit.


  • Open Access

    Repositioning and Characterization of 1-(Pyridin-4-yl)pyrrolidin-2-one Derivatives as Plasmodium Cytoplasmic Prolyl-tRNA Synthetase Inhibitors

    by Masanori Okaniwa, Akira Shibata, Atsuko Ochida, Yuichiro Akao, Karen L. White, David M. Shackleford, Sandra Duffy, Leonardo Lucantoni, Sumanta Dey, Josefine Striepen, et al.

    Prolyl-tRNA synthetase (PRS) is a clinically validated antimalarial target. Screening of a set of PRS ATP-site binders, initially designed for human indications, led to identification of 1-(pyridin-4-yl)pyrrolidin-2-one derivatives representing a novel antimalarial scaffold. Evidence designates cytoplasmic PRS as the drug target. The frontrunner 1 and its active enantiomer 1-S exhibited low-double-digit nanomolar activity against resistant Plasmodium falciparum (Pf) laboratory strains and development of liver schizonts. No cross-resistance with strains resistant to other known antimalarials was noted. In addition, a similar level of growth inhibition was observed against clinical field isolates of Pf and P. vivax. The slow killing profile and the relative high propensity to develop resistance in vitro (minimum inoculum resistance of 8 × 105 parasites at a selection pressure of 3 × IC50) constitute unfavorable features for treatment of malaria. However, potent blood stage and antischizontal activity are compelling for causal prophylaxis which does not require fast onset of action. Achieving sufficient on-target selectivity appears to be particularly challenging and should be the primary focus during the next steps of optimization of this chemical series. Encouraging preliminary off-target profile and oral efficacy in a humanized murine model of Pf malaria allowed us to conclude that 1-(pyridin-4-yl)pyrrolidin-2-one derivatives represent a promising starting point for the identification of novel antimalarial prophylactic agents that selectively target Plasmodium PRS.


  • Open Access

    A Plasmodium vivax experimental human infection model for evaluating efficacy of interventions

    by Katharine A. Collins, Claire Y.T. Wang, Matthew Adams, Hayley Mitchell, Greg J. Robinson, Melanie Rampton, Suzanne Elliott, Anand Odedra, David Khoury, Emma Ballard, et al.

    BACKGROUND. Interventions that interrupt Plasmodium vivax transmission or eliminate dormant P. vivax liver-stage parasites will be essential for malaria elimination. Development of these interventions has been hindered by the lack of P. vivax in vitro culture and could be accelerated by a safe and reproducible clinical model in malaria-naive individuals. METHODS. Healthy, malaria-naive adults were enrolled in 2 studies to assess the safety, infectivity, and transmissibility of a new P. vivax isolate. Participants (Study 1, n = 2; Study 2, n = 24) were inoculated with P. vivax–infected red blood cells to initiate infection, and were treated with artemether-lumefantrine (Study 1) or chloroquine (Study 2). Primary endpoints were safety and infectivity of the new isolate. In Study 2, transmission to mosquitoes was also evaluated using mosquito feeding assays, and sporozoite viability was assessed using in vitro cultured hepatocytes. RESULTS. Parasitemia and gametocytemia developed in all participants and was cleared by antimalarial treatment. Adverse events were mostly mild or moderate and none were serious. Sixty-nine percent of participants (11/16) were infectious to Anopheles mosquitoes at peak gametocytemia. Mosquito infection rates reached 97% following membrane feeding with gametocyte-enriched blood, and sporozoites developed into liver-stage schizonts in culture. CONCLUSION. We have demonstrated the safe, reproducible, and efficient transmission of P. vivax gametocytes from humans to mosquitoes, and have established an experimental model that will accelerate the development of interventions targeting multiple stages of the P. vivax life cycle. TRIAL REGISTRATION. ACTRN12614000930684 and ACTRN12616000174482. FUNDING. (Australian) National Health and Medical Research Council Program Grant 1132975 (Study 1). Bill and Melinda Gates Foundation (OPP1111147) (Study 2).


  • Orthoscuticellines A–E, β-Carboline Alkaloids from the Bryozoan Orthoscuticella ventricosa Collected in Australia

    by Guy Kleks, Sandra Duffy, Leonardo Lucantoni, Vicky M. Avery, Anthony R. Carroll

    Antiplasmodial high-throughput screening of extracts derived from marine invertebrates collected from northern NSW, Australia, resulted in the methanol extract of the bryozoan Orthoscuticella ventricosa being identified as inhibitory toward the 3D7 strain of Plasmodium falciparum. Purification of this extract resulted in two new bis-β-carbolines that possess a cyclobutane moiety, orthoscuticellines A and B (1 and 2), three new β-carboline alkaloids, orthoscuticellines C–E (3–5), and six known compounds, 1-ethyl-4-methylsulfone-β-carboline (6), 1-ethyl-β-carboline (7), 1-acetyl-β-carboline (8) 1-(1′-hydroxyethyl)-β-carboline (9), 1-methoxycarbonyl-β-carboline (10), and 1-vinyl-β-carboline (11). The structures of all compounds were determined from analysis of MS and 1D and 2D NMR data. The compounds showed modest antiplasmodial activity against P. falciparum in the range of 12–21 μM.


  • Desymmetrization Reactions of Indigo with Grignard Reagents for the Synthesis of Selective Antiplasmodial [1H,3′H]-3-Aryl-2,2′-diindol-3′-ones

    by Nicholas M. Butler, John B. Bremner, Anthony C. Willis, Leonardo Lucantoni, Vicky M. Avery, Paul A. Keller

    The nucleophilic addition of organomagnesium and organolithium species to the cheap and robust natural dye indigo led to desymmetrization of the heterocyclic nucleus via a Grignard addition–dehydration procedure. Twenty-seven diversely functionalized [1H,3′H]-3-substituted 2,2′-diindol-3′-ones were synthesized by this methodology, with several showing submicromolar inhibition and exquisite selectivity against P. falciparum parasites (3D7 and Dd2 strains) in vitro. This work demonstrates the utility of indigo dye as a highly versatile scaffold for the synthesis of structurally diverse, bioactive heterocycles.


  • Cascade reactions of indigo with oxiranes and aziridines: efficient access to dihydropyrazinodiindoles and spiro-oxazocinodiindoles

    by Nicholas M. Butler, Rudi Hendra, John B. Bremner, Anthony C. Willis, Leonardo Lucantoni, Vicky M. Avery, Paul A. Keller

    The base-initiated alkylation of the abundant natural dye indigo 1 with ring-strained electrophiles results in the unprecedented, one-pot synthesis of functionalised dihydropyrazino[1,2-a:4,3-a′]diindoles, dihydroepoxy[1,5]oxazocino[5,4-a:3,2-b′]diindoles, and dihydrodiazepino[1,2-a:4,3-a′]diindoles, resulting from intramolecular ring opening-expansion cyclisation processes of their parent oxiranes and aziridines. Regiochemical and stereochemical aspects of the reactions are reported together with integrated mechanistic proposals. This new indigo cascade chemistry should have broad applicability in the synthesis of chemical architectures, not readily-accessible by other means. The three-step synthesis of the useful synthetic precursor (R)-2-(chloromethyl)-1-tosylaziridine 14 is also described. Initial biological activity investigations into these new 2,2′-dindolyl-based heterocyclic derivatives revealed potent, selective antiplasmodial activity in vitro for several isolated structures, with IC50 values as low as 76.6 nM for (±)-8, while demonstrating low human cell toxicity.


  • Antiplasmodial β-Triketone–Flavanone Hybrids from the Flowers of the Australian Tree Corymbia torelliana

    by Sarath P. D. Senadeera, Leonardo Lucantoni, Sandra Duffy, Vicky M. Avery, Anthony R. Carroll

    The methanol extract of the flowers of the Australian eucalypt tree Corymbia torelliana yielded six new β-triketone–flavanone hybrids, torellianones A–F (1–6), the tetrahydroxycyclohexane torellianol A (7), and known β-triketones (4S)-ficifolidione (8) and (4R)-ficifolidione (9), and β-triketone–flavanones kunzeanone A (10) and kunzeanone B (11). Torellianones A and B, C and D, and E and F were each isolated as inseparable diastereomeric mixtures. Exchange correlations observed in a ROESY spectrum indicated that 5 and 6 also interconverted between stable conformers. The structures of 1–7 were elucidated from the analysis of 1D/2D NMR and MS data. Relative configurations of torellianones C–F and torrellianol A were determined from analysis of ROESY data. Compounds 1–10 were tested for antiplasmodial activity against a drug-sensitive (3D7) strain of Plasmodium falciparum, with 3–6 and 8–10 showing limited antiplasmodial activity, with IC50 values ranging from 3.2 to 16.6 μM.